Ramucirumab is indicated for:
1. The treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression during or after fluoropyrimidine- or platinum-containing chemotherapy, as monotherapy or in combination with paclitaxel.
2. The treatment of metastatic non-small cell lung cancer (NSCLC) with disease progression during or after platinum-based chemotherapy, in combination with docetaxel.
3. The treatment of metastatic colorectal cancer (mCRC) with disease progression during or after bevacizumab, oxaliplatin, and fluoropyrimidine-based chemotherapy, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil).
4. As the first FDA-approved biomarker-driven therapy for hepatocellular carcinoma (approved in May 2019).